WLY

#1777
John Wiley & Sons, Inc. Common Stock
53.8 8 USD
+0.03%
Market Price
Sektor: Kommunikationsdienste
Basis: USD
Gewinnwährung: USD
Tagesspanne
53.83
54.52
Jahresspanne
28.38
57.45
Tagesänderung
+2.80%
Monatliche Änderung
+1.64%
6 month change
+79.06%
Jahresänderung
+34.70%
Vorheriger Schlusskurs
52.4 1
Open
54.5 0
Tief
53.8 3
Hoch
54.5 2
Volumen
68
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
JOHN WILEY & SONS, INC. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
JOHN WILEY & SONS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
JOHN WILEY & SONS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
JOHN WILEY & SONS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
JOHN WILEY & SONS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
JOHN WILEY & SONS, INC. current report, Q2 FY2026
8-K
Annual report, FY2026
JOHN WILEY & SONS, INC. annual report, FY2026
10-K
Current report, Q1 FY2026
JOHN WILEY & SONS, INC. current report, Q1 FY2026
8-K
Quarterly report, Q3 FY2026
JOHN WILEY & SONS, INC. quarterly report, Q3 FY2026
10-Q

2025

Current report, Q4 FY2025
JOHN WILEY & SONS, INC. current report, Q4 FY2025
8-K

JOHN WILEY & SONS, INC. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Company: JOHN WILEY & SONS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2025 (Event Date)
Press Release Date: March 5, 2025
Context: The filing reports the election of a new director to the Board of Directors and details associated compensatory arrangements.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation.

Material Changes

  • Board Composition: Dr. Karen N. Madden was elected to the Board of Directors effective February 28, 2025.
  • Committee Assignment: Dr. Madden was appointed to the Audit Committee.
  • Independence: The Board determined Dr. Madden is "independent" under NYSE rules.

Guidance, Outlook, and Management Commentary

Compensatory Arrangements: As a non-employee director, Dr. Madden will receive:

  • Annual Cash Retainer: $85,000.
  • Annual Stock Award: Restricted Class A Common Stock valued at $130,000 (share count based on closing NYSE price on grant date).
Vesting Schedule: Restricted shares vest on the earliest of:
  1. The day before the next Annual Meeting following the grant.
  2. The director's death or disability.
  3. A Change in Control.
Other Benefits: Eligibility to defer cash/stock awards and participation in the Matching Gift Program. Risks/Contingencies: The filing states there were no undisclosed arrangements regarding Dr. Madden's selection and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.

Investor Verification Checklist

  • Verify Dr. Karen N. Madden's professional background and independence status via the attached press release (Exhibit 99.1).
  • Confirm the impact of the new director on the Audit Committee's composition and oversight capabilities.
  • Review the Company's 2022 Omnibus Stock and Long-Term Incentive Plan for details on vesting conditions and deferral options.
  • Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.

Nachrichten